Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences

Threshold Pharmaceuticals Announces Presentations and Webcasts at Three 
Upcoming Investor Conferences 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/09/13 --  Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry
Selick, Ph.D., Threshold's Chief Executive Officer, will present a
company overview at three upcoming investor conferences: 

--  BofA Merrill Lynch 2013 Healthcare Conference, May 15, 2013, at 4:00
    p.m. ET;
--  2013 UBS Global Healthcare Conference, May 22, 2013, at 8:30 a.m. ET;
--  Jeffries 2013 Global Healthcare Conference, June 6, 2013, at 9:30 a.m.

Alive webcast of each presentation will be available under Webcasts in
the Investors section of A replay of each
presentation will be archived on the site for 30 days. 
About Threshold Pharmaceuticals 
 Threshold Pharmaceuticals, Inc. is
a biotechnology company focused on the discovery and development of
drugs targeting tumor hypoxia, the low oxygen condition found in the
microenvironments of most solid tumors as well as the bone marrows of
some patients with hematologic malignancies. This approach offers
broad potential to treat a variety of cancers. By selectively
targeting tumor cells, we are building a pipeline of drugs that hold
promise to be more effective and less toxic to healthy tissues than
conventional anticancer drugs. For additional information, please
visit our website ( 
Forward-Looking Statements
 Except for statements of historical fact,
the statements in this press release are forward-looking statements,
including statements regarding the potential therapeutic uses and
benefits of its product candidates. These statements involve risks
and uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and
expense required to conduct such clinical trials and analyze data,
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues and
efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Quarterly Report on Form 10-Q, which has been filed with the
Securities and Exchange Commission on May 2, 2013 and is available
from the SEC's website ( and on our website
( under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
Press spacebar to pause and continue. Press esc to stop.